Gossip, Lies And Then Luminespib

To address informative censoring, we fitted logistic regression models to calculate the inverse probability of censoring weights (IPCWs) at each time interval. As done with IPTWs, we used the same covariates for the numerator and denominator of the stabilized IPCW modeling the calculated probability of observed censorship. As large censoring weights were not observed, truncation was not performed for IPCW values. The final stabilized weights were calculated as the product of the stabilized IPTWs and stabilized IPCWs. We estimated the odds ratio (OR) using a generalized estimating equation that included ESA dose category and the final stabilized weights on the basis of all baseline covariates. The ESA dose category of Luminespib clinical trial data were missing for less than 5% and 1%, respectively. To further impute missing time-varying covariates in each time window, we used last-value carried forward. All analyses RO4929097 purchase were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC). 3. Results 3.1. Patient's Characteristics Baseline characteristics of the overall patient cohort and stratified across ESA categories are summarized in Table 1. During the baseline quarter, there were 6?644 (5%), 23?314 (18%), 26?852 (21%), 21?487 (17%), 15?278 (12%), and 35?023 (27%) patients receiving a weekly ESA dose of Fleroxacin of Weights The distribution of the weights is displayed in Table 2. Stabilized weights had a maximum value of 80.9 and 78.9 in the overall and incident patient cohorts, respectively. The mean stabilized weights were 0.84 and 0.88, respectively. Table 2 Weight distribution for marginal structural model across 3-month time intervals. 3.3. Weekly ESA Dose and All-Cause Mortality Weekly ESA doses ��18?000?U/week were associated with higher risks of death as compared with a weekly epoetin-�� dose of